Articles

  • 2 days ago | tradingview.com | Dean Seal

    Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, DemandATDAlimentation Couche-Tard logged a lower profit in its fiscal fourth quarter as lower prices and demand for fuel in the U.S. ate into its revenue. The Canadian convenience-store chain posted a profit of $439.4 million, or 46 cents a share, for the quarter ended April 27. That's down slightly from $453 million, or 47 cents a share, in the comparable quarter a year earlier.

  • 2 days ago | tradingview.com | Dean Seal

    Micron Technology 3Q Profit Soars as AI Boom Boosts SalesMUMicron Technology notched a big leap in sales and earnings for its latest completed quarter amid booming demand for artificial-intelligence-driven memory. The memory-chip maker posted a profit of $1.89 billion, or $1.68 a share, for the quarter ended May 29. That is up from $332 million, or 30 cents a share, in the comparable quarter a year earlier. Stripping out one-time items, adjusted earnings were $1.91 a share.

  • 2 days ago | wsj.com | Dean Seal

    Global dealmaking in the first half of the year fell to a two-decade low as tariffs, high interest rates, a choppy market and uncertainty around the Trump administration’s policies stalled a rebound in M&A activity. The worldwide tally of mergers, acquisitions, divestitures, financings and joint ventures so far in 2025 was down 16% year-over-year at 16,663, its lowest level since 2005, according to financial data company Mergermarket. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.

  • 4 days ago | tradingview.com | Dean Seal

    FTC Resolves Antitrust Probe Into Omnicom-Interpublic MergerIPGOMCThe Federal Trade Commission said it struck a deal with Omnicom Group and Interpublic Group that resolves its antitrust concerns with their proposed $13.5 billion merger.

  • 1 week ago | tradingview.com | Dean Seal

    Incyte Says FDA Extended Review Period for OpzeluraINCYIncyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11. The biopharmaceutical company said Friday that the U.S. Food and Drug Administration has extended the review period by three months to Sept.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
1K
Tweets
2K
DMs Open
No
Dean Seal
Dean Seal @JDeanSeal
6 Jun 24

RT @sabelaojeaguix: I spoke to the @WSJ team about what went wrong with Rent the Runway. Special thanks to @eadean1418. Go check out the vi…

Dean Seal
Dean Seal @JDeanSeal
3 Jun 24

RT @WSJCFO: Hertz Hires Finance Chief from Spirit Airlines https://t.co/AOlsmHPu4L via @WSJ @JDeanSeal

Dean Seal
Dean Seal @JDeanSeal
30 May 24

RT @ukpapers: 🇺🇸 ConocoPhillips To Buy Marathon Oil ▫The $17.1 billion deal marks the latest major consolidation in the energy sector ▫@JD…